Fredrik SjövallChief Executive Officer
Mr Fredrik Sjövall. Chief Executive Officer. Graduated from the Chalmers University of Technology (MSc). Previous appointments include CEO at PharmaSurgics and Lipopeptide (currently Promore pharma). Sjövall has spent more than 10 years as the CEO of early stage companies in the life science industry.
Per GerdeChief Scientific Officer
Associate Professor of Inhalation Toxicology. Scientist at the Division of Physiology, Institute of Environmental Medicine at the Karolinska Institutet. Previous appointments include scientist at the Lovelace Respiratory Research Institute (1993– 1998), scientist at the Swedish National Institute of Occupational Health (1991–1996), and postdoctoral fellow at the Lovelace Respiratory Research Institute (1989–1991). Dr. Gerde has published approx. 30 peer reviewed scientific papers. He is also the main inventor of six patent families with related patent applications.
Michael OwensChief Financial Officer
With a BSBA (Bachelor Business Administration in accounting and auditing Michael Owens has held executive finance positions in both the US and Sweden. From 2007 – 2012 he was Group Controller of Karolinska Development, playing a key role in successfully taking the company public in 2011. He has extensive executive experience in the medtech research field, guiding companies surely through a complex legislative and fiscal landscape.
Tom SunderlinCommercialization Manager
Tom Sundelin has over 20 years’ experience in Life Sciences, including 10 in the global inhalation arena. His executive roles have included CEO (Quickels Systems AB and IM-Medico AB), Global Sales Director (Aerocrine AB) and Member of the Board (Naslund Medical). Helping smaller European and Scandinavian companies commercialize on a global level, Tom has experience building subsidiaries, managing large networks of distributors, selling, marketing and carrying out reimbursement and health economy work in the clinical setting.
Maria MalmlöfDirector of Projects
With a M.Sc. in Biotechnology from Sweden’s KTH Royal Institute of Technology and PhD research ongoing, Maria Malmlöf has co-authored a list of publications in inhalation R&D, specializing in in vitro dissolution. Maria has played a key role in the evolution of ISAB’s in vitro dissolution system DissolvIt and its 3D cell culturing technology XposeALI. As ISAB’s Director of Projects her expertise and experience guides all ongoing customer and contract research and development projects.
Mark Du BoisIR & Communications Officer
Mark is a copywriter and communicator specializing in B2B communication, based in Stockholm. He teaches regularly at Berghs School of Communication and before that was a full-time consultant for six years for B2B PR agency Journalistgruppen (currently Nordic Morning). He is a graduate of the University of Essex, UK.